Efficacy and safety by body weight decile in patients treated with tildrakizumab 100 mg for 28 weeks: Pooled data analysis of reSURFACE 1 and reSURFACE 2

Main Article Content

Alan M Menter
Zoe Draelos
Jayme Heim
Ranga Gogineni
Christopher EM Griffiths


tildrakizumab, psoriasis, plaque psoriasis, body weight, obesity


1. Pirro F, et al. Clin Drug Investig. 2021;41(10):917–25.

2. ILUMYA® (tildrakizumab). Full prescribing information; April 2022.

3. Reich K, et al. Lancet. 2017;390(10091):276–88.

Most read articles by the same author(s)

1 2 3 4 > >>